Menu

MorphoSys is dedicated to become a fully integrated biopharmaceutical company. Our business strategy brings more value for patients, investors and partners.

More Info

First MorphoSys-antibody approved
Tremfya® (Guselkumab) now available in US, Europe and Canada!

More Info

We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.

Find out more about our therapeutic pipeline.

More Info

MorphoSys's vision

MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

learn more about the company

Latest
news

05/11/2018
MorphoSys AG Announces Third Quarter 2018 Results
Read Media Release
01/11/2018
MorphoSys to Present Data on Investigational Drugs MOR208 and MOR202 in...
Read Media Release
29/10/2018
MorphoSys to Host Q3 2018 Conference Call on November 6, 2018
Read Media Release
21/10/2018
MorphoSys's Licensing Partner GSK has Reported Data on GSK3196165...
Read Media Release
19/10/2018
MorphoSys's Licensee Janssen has Reported That New Tremfya(R) (...
Read Media Release
25/09/2018
MorphoSys Announces its Licensee Janssen has Initiated a Phase 3 Trial (...
Read Media Release
17/09/2018
MorphoSys and LEO Pharma Expand Strategic Alliance to Develop Peptide-...
Read Media Release
13/09/2018
MorphoSys and Galapagos Announce Start of a Phase 1 Subcutaneous Bridging...
Read Media Release
13/09/2018
MorphoSys Announces That its Licensee Janssen has Reported That Tremfya(R...
Read Media Release
12/09/2018
MorphoSys and Galapagos Announce U.S. Antitrust Clearance for Global...
Read Media Release

November 6, 2018
Conference Call & Webcast
Q3 Results 2018

Full details

 

 

 

 

Interview with
Simon Moroney, CEO